Rationale and design of an adaptive phase 2b/3 clinical trial of selepressin for adults in septic shock: Selepressin evaluation programme for sepsis-induced shock - Adaptive clinical trial

Annals of the American Thoracic Society

Volumn 15, Issue 2, 2018, Pages 250-257

  Lewis, Roger J ^a,b,c,d   Angus, Derek C ^e   Laterre, Pierre François ^f   Kjølbye, Anne Louise ^g   Van Der Meulen, Egbert ^g   Blemings, Allan ^g   Graves, Todd ^d   Russell, James A ^h   Carlsen, Jan E ⁱ   Jacobsen, Karsten ^g   Yealy, Donald M ^e   Opal, Steven M ^j   Windeløv, Nis A ^g   François, Bruno ^k   Perner, Anders ^l   Pickkers, Peter ^m   Berry, Scott M ^d  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BERRY CONSULTANTS   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^g Ferring Pharmaceuticals AS   (Denmark)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁱ StraDevo A S   (Denmark)

^j BROWN UNIVERSITY   (United States)

^k LIMOGES UNIVERSITY HOSPITAL   (France)

^l International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^m RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

Adaptive clinical trial design; Septic shock; Vasopressor treatment

Indexed keywords

DOPAMINE; EPINEPHRINE; NORADRENALIN; PHENYLEPHRINE; PLACEBO; SELEPRESSIN; VASOPRESSIN; VASOCONSTRICTOR AGENT; VASOPRESSIN DERIVATIVE; VASOPRESSIN RECEPTOR; VASOPRESSIN, PHE(2)-ILE(3)-HGN(4)-ORN(IPR)(8)-;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEPTIC SHOCK; STUDY DESIGN; TREATMENT OUTCOME; TREATMENT RESPONSE; AGONISTS; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPLICATION; DRUG MONITORING; FEMALE; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; METHODOLOGY; PROCEDURES; RISK ASSESSMENT;

ADULT; CLINICAL PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HUMANS; HYPOTENSION; INFUSIONS, INTRAVENOUS; MALE; RECEPTORS, VASOPRESSIN; RESEARCH DESIGN; RISK ASSESSMENT; SHOCK, SEPTIC; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS; VASOPRESSINS;

EID: 85045343570     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201708-669SD     Document Type: Article

References (22)

1. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med 2013; 369: 840-851.
2. Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, Liu VX, Deutschman CS, et al.; Sepsis Definitions Task Force. Developing a new definition and assessing new clinical criteria for septic shock: for the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315: 775-787.
3. Angus DC The search for effective therapy for sepsis: back to the drawing board? JAMA 2011; 306: 2614-2615.
4. Dolgin E. Trial failure prompts soul-searching for critical-care specialists. Nat Med 2012; 18: 1000.
5. Cohen J, Vincent JL, Adhikari NKJ, Machado FR, Angus DC, Calandra T, et al. Sepsis: a roadmap for future research. Lancet Infect Dis 2015; 15: 581-614.
6. Perner A, Gordon AC, Angus DC, Lamontagne F, Machado F, Russell JA, et al. The intensive care medicine research agenda on septic shock. Intensive Care Med 2017; 43: 1294-1305.
7. 1a receptor full agonist for the treatment of vasodilatory hypotension. J Pharmacol Exp Ther 2011; 337: 786-796.
8. Maybauer MO, Maybauer DM, Enkhbaatar P, Laporte R, Wiśniewska H, Traber LD, et al. The selective vasopressin type 1a receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis. Crit Care Med 2014; 42: e525-e533.
9. 1a agonism attenuates vascular dysfunction and fluid accumulation in ovine severe sepsis. Am J Physiol Heart Circ Physiol 2012; 303: H1245-H1254.
10. Rehberg S, Ertmer C, Vincent JL, Morelli A, Schneider M, Lange M, et al. Role of selective V1a receptor agonism in ovine septic shock. Crit Care Med 2011; 39: 119-125.
11. Su F, He X, Taccone FS, Xie K, Mouhamed M, Kjølbye AL, et al. 123: Early administration of the selective V1a receptor agonist selepressin is superior to arginine vasopressin or norepinephrine in a sheep model of septic shock [abstract 123]. Crit Care Med 2012; 40(12, Suppl 1): 1-328.
12. 1A receptor agonist, selepressin, is superior to arginine vasopressin and to norepinephrine in ovine septic shock. Crit Care Med 2016; 44: 23-31.
13. Saad AF, Maybauer MO. The role of vasopressin and the vasopressin type V1a receptor agonist selepressin in septic shock. J Crit Care 2017; 40: 41-45.
14. Russell JA, Vincent JL, Kjølbye AL, Olsson H, Blemings A, Spapen H, et al. Selepressin, a novel selective vasopressin V1a agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients. Crit Care 2017; 21: 213.
15. Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA 2014; 311: 1308-1316.
16. Iwashyna TJ, Angus DC. Declining case fatality rates for severe sepsis: good data bring good news with ambiguous implications. JAMA 2014; 311: 1295-1297.
17. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315: 801-810.
18. van Elteren PH. On the combination of independent two sample tests of Wilcoxon. Bull Inst Int Stat 1960; 37: 351-361.
19. Cao J, Zhang S. Multiple comparison procedures. JAMA 2014; 312: 543-544.
20. Calis KA, Archdeacon P, Bain R, DeMets D, Donohue M, Elzarrad MK, et al. Recommendations for data monitoring committees from the Clinical Trials Transformation Initiative. Clin Trials 2017; 14: 342-348.
21. U.S. Food and Drug Administration. Special Protocol Assessment: Guidance for Industry [Draft Guidance, 2016 May]. Available at: https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm498793.pdf
22. Meurer WJ, Lewis RJ, Berry DA. Adaptive clinical trials: a partial remedy for the therapeutic misconception? JAMA 2012; 307: 2377-2378.